A Sequential Phase I Study of MEK1/2 Inhibitors PD-0325901 or Binimetinib Combined With cMET Inhibitor PF-02341066 in Patients With RAS Mutant and RAS Wild Type (With Aberrant c-MET) Colorectal Cancer
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 17 Jan 2018
At a glance
- Drugs Binimetinib (Primary) ; Crizotinib (Primary) ; PD 325901 (Primary)
- Indications Colorectal cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Acronyms MErCuRIC1
- 14 Nov 2017 Planned number of patients changed from 78 to 92.
- 19 Sep 2017 Status changed from recruiting to active, no longer recruiting.
- 19 Sep 2017 Planned End Date changed from 1 Apr 2018 to 31 Dec 2018.